RO 7283420
Alternative Names: RG-63441; RO-7283420Latest Information Update: 28 Mar 2025
At a glance
- Originator Roche
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 28 Mar 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in United Kingdom (IV, Infusion)
- 28 Jan 2025 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in France (IV, Infusion)
- 28 Dec 2024 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Second-line therapy or greater) in Australia (IV, Infusion)